- CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.
CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.
Oncogene (2017-04-11)
E Zoni, L Chen, S Karkampouna, Z Granchi, E I Verhoef, F La Manna, J Kelber, R C M Pelger, M D Henry, E Snaar-Jagalska, G J L H van Leenders, L Beimers, P Kloen, P C Gray, G van der Pluijm, M Kruithof-de Julio
PMID28394345
RESUMEN
CRIPTO (CR-1, TDGF1) is a cell surface/secreted oncoprotein actively involved in development and cancer. Here, we report that high expression of CRIPTO correlates with poor survival in stratified risk groups of prostate cancer (PCa) patients. CRIPTO and its signaling partner glucose-regulated protein 78 (GRP78) are highly expressed in PCa metastases and display higher levels in the metastatic ALDH
MATERIALES
Referencia del producto
Marca
Descripción del producto